Abstract

The 2020 SARS-CoV-2 pandemic is caused by a zoonotic coronavirus transmitted to humans, similar to earlier events. Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross-neutralizing, antibodies to the new species in humans is unclear. The question is particularly relevant for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment. Testing 54 intravenous immunoglobulin preparations, produced from plasma collected in Europe and the United States, confirmed highly potent neutralization of a seasonal coronavirus; however, no cross-neutralization of the new SARS-CoV-2 was seen.

中文翻译：

---

2020 年大流行之前收集的血浆产生的静脉注射免疫球蛋白无法中和 SARS-CoV-2。

摘要

2020 年 SARS-CoV-2 大流行是由传播给人类的人畜共患冠状病毒引起的，与之前的事件类似。其他季节性传播的冠状病毒是否会在人类体内诱导针对新物种的交叉反应、甚至可能交叉中和的抗体尚不清楚。这个问题与免疫缺陷患者尤其相关，因为他们的健康取决于免疫球蛋白制剂的治疗，而免疫球蛋白制剂需要含有针对环境中病原体的中和抗体。对从欧洲和美国收集的血浆生产的 54 种静脉注射免疫球蛋白制剂进行了测试，证实对季节性冠状病毒具有高效中和作用；然而，没有发现新 SARS-CoV-2 的交叉中和作用。